These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38675824)

  • 1. Anti-Herpes Zoster Vaccination of Fragile Patients in Hospital Setting: A Nudge Intervention in Italy.
    De Caro F; Malatesta F; Pecoraro N; Capunzo M; Carpinelli L; Caruccio S; Cersosimo G; Costantino M; Giordano C; Longanella W; Patella V; Saggese Tozzi A; Savarese G; Sinopoli P; Vozzella EA; Moccia G
    Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
    Parikh R; Widenmaier R; Lecrenier N
    Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.
    Pirrotta P; Tavares-Da-Silva F; Co M; Lecrenier N; Hervé C; Stegmann JU
    Drug Saf; 2021 Dec; 44(12):1341-1353. PubMed ID: 34622421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021-23.
    Stefanizzi P; Moscara L; Palmieri C; Martinelli A; Di Lorenzo A; Venerito V; Germinario CA; Tafuri S
    Vaccine; 2024 Apr; 42(12):2966-2974. PubMed ID: 38582693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.
    Stadtmauer EA; Sullivan KM; El Idrissi M; Salaun B; Alonso Alonso A; Andreadis C; Anttila VJ; Bloor AJ; Broady R; Cellini C; Cuneo A; Dagnew AF; Di Paolo E; Eom H; González-Rodríguez AP; Grigg A; Guenther A; Heineman TC; Jarque I; Kwak JY; Lucchesi A; Oostvogels L; Polo Zarzuela M; Schuind AE; Shea TC; Sinisalo UM; Vural F; Yáñez San Segundo L; Zachée P; Bastidas A
    Hum Vaccin Immunother; 2021 Nov; 17(11):4144-4154. PubMed ID: 34406911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individual and Contextual Determinants of Flu Vaccination Adherence: A University Nudge Intervention.
    Pecoraro N; Malatesta F; Carpinelli L; Fornino D; Giordano C; Moccia G; Perillo M; Capunzo M; Savarese G; De Caro F
    Int J Environ Res Public Health; 2023 May; 20(10):. PubMed ID: 37239626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
    Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng HF
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1567-1575. PubMed ID: 33043821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Public health impact of herpes zoster vaccination on older adults in Hong Kong.
    Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C
    Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020.
    Orru' S; Bierbaum S; Enk A; Hengel H; Hoffelner M; Huzly D; Keller-Stanislawski B; Mahler V; Mockenhaupt M; Oberle D
    Euro Surveill; 2023 Dec; 28(50):. PubMed ID: 38099347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knowledge, Attitudes and Practices Survey of Recombinant Zoster Vaccine among Cardiologists and Cardiac Nurses in Italy.
    Ponticelli D; Antonazzo IC; Losa L; Zampella A; Di Marino F; Mottola G; Fede MN; Gallucci F; Magliuolo R; Rainone A; Del Giudice C; Arcari A; Ferrara P
    Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256354
    [No Abstract]   [Full Text] [Related]  

  • 11. The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy.
    Volpi A; Boccalini S; Dari S; Clarke C; Curran D; Loiacono I; Pitrelli A; Puggina A; Tosatto R; Van Oorschot D; Franco E
    Hum Vaccin Immunother; 2020; 16(2):327-334. PubMed ID: 31442095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States.
    Lu A; Sun Y; Porco TC; Arnold BF; Acharya NR
    Ophthalmology; 2021 Dec; 128(12):1699-1707. PubMed ID: 33892049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
    Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant zoster vaccine (Shingrix
    Singh G; Song S; Choi E; Lee PB; Nahm FS
    Korean J Pain; 2020 Jul; 33(3):201-207. PubMed ID: 32606264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
    Lecrenier N; Beukelaers P; Colindres R; Curran D; De Kesel C; De Saegher JP; Didierlaurent AM; Ledent EY; Mols JF; Mrkvan T; Normand-Bayle M; Oostvogels L; Da Silva FT; Vassilev V; Vinals C; Brecx A
    Expert Rev Vaccines; 2018 Jul; 17(7):619-634. PubMed ID: 30028651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults.
    Janusz CB; Anderson TC; Leidner AJ; Lee GM; Dooling K; Prosser LA
    Hum Vaccin Immunother; 2022 Nov; 18(5):2060668. PubMed ID: 35476029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries.
    Goud R; Lufkin B; Duffy J; Whitaker B; Wong HL; Liao J; Lo AC; Parulekar S; Agger P; Anderson SA; Wernecke M; MaCurdy TE; Weintraub E; Kelman JA; Forshee RA
    JAMA Intern Med; 2021 Dec; 181(12):1623-1630. PubMed ID: 34724025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: A retrospective cohort study.
    Sun Y; Jackson K; Dalmon CA; Shapiro BL; Nie S; Wong C; Arnold BF; Porco TC; Acharya NR
    Vaccine; 2021 Jun; 39(29):3974-3982. PubMed ID: 34116874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review.
    Giannelos N; Ng C; Curran D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2168952. PubMed ID: 36916240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals.
    Curran D; Kim JH; Matthews S; Dessart C; Levin MJ; Oostvogels L; Riley ME; Schmader KE; Cunningham AL; McNeil SA; Schuind AE; Andrew MK;
    J Am Geriatr Soc; 2021 Mar; 69(3):744-752. PubMed ID: 33197294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.